These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
529 related articles for article (PubMed ID: 14565644)
21. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
22. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487 [TBL] [Abstract][Full Text] [Related]
23. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice. Xun C; Brown SA; Jennings CD; Henslee-Downey PJ; Thompson JS Transplantation; 1993 Aug; 56(2):409-17. PubMed ID: 8356598 [TBL] [Abstract][Full Text] [Related]
24. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. Wang FS; Liu MX; Zhang B; Shi M; Lei ZY; Sun WB; Du QY; Chen JM World J Gastroenterol; 2002 Jun; 8(3):464-8. PubMed ID: 12046071 [TBL] [Abstract][Full Text] [Related]
25. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
26. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871 [TBL] [Abstract][Full Text] [Related]
31. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells. Xun CQ; Thompson JS; Jennings CD; Brown SA Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742 [TBL] [Abstract][Full Text] [Related]
33. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679 [TBL] [Abstract][Full Text] [Related]
34. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Schmidt-Wolf GD; Negrin RS; Schmidt-Wolf IG Ann Hematol; 1997 Feb; 74(2):51-6. PubMed ID: 9063373 [TBL] [Abstract][Full Text] [Related]
35. [The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia]. Li Y; Huang SL; Zhang XC; Fang JP; Wu YF; Wei J; Huang WG; Zhou DH; Huang K; Lin YC Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):39-43. PubMed ID: 18512314 [TBL] [Abstract][Full Text] [Related]
36. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. Zhu HG; Zollner TM; Klein-Franke A; Anderer FA J Cancer Res Clin Oncol; 1994; 120(7):383-8. PubMed ID: 7514604 [TBL] [Abstract][Full Text] [Related]
37. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560 [TBL] [Abstract][Full Text] [Related]
38. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292 [TBL] [Abstract][Full Text] [Related]
39. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Mehta BA; Schmidt-Wolf IG; Weissman IL; Negrin RS Blood; 1995 Nov; 86(9):3493-9. PubMed ID: 7579455 [TBL] [Abstract][Full Text] [Related]
40. [Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo]. Yang XJ; Huang JA; Lei W; Zhu YB; Zhang XG Ai Zheng; 2006 Nov; 25(11):1329-33. PubMed ID: 17094896 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]